Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt's Lymphoma

被引:0
|
作者
Jaffari, Syed Muhammad Ibne Ali [1 ]
Hashmi, Masooma [2 ]
Hashmi, Abdul Wasey [1 ]
Nisar, Samaha [1 ]
Ashraf, Hafsa [1 ]
Tariq, Ghufran [3 ]
Farooq, Arslan [4 ]
Awan, Javeria [5 ]
Zaidi, Wasey Syed Muhammad Jawad [6 ,7 ]
Kaneez, Mehwish [6 ,7 ]
机构
[1] Shalamar Med & Dent Coll, Pediat, Lahore, Pakistan
[2] Royal Wolverhampton NHS Trust, Walsall Manor Hosp, Internal Med, Walsall, England
[3] Arif Mem Teaching Hosp, Pediat, Lahore, Pakistan
[4] Combined Mil Hosp, Internal Med, Lahore, Pakistan
[5] Rawalpindi Med Univ, Pediat, Rawalpindi, Pakistan
[6] Holy Family Hosp, Pediat, Rawalpindi, Pakistan
[7] Shaukat Khanum Mem Canc Hosp & Res Ctr, Pediat Oncol, Lahore, Pakistan
关键词
Categories; Pediatrics; Disease; Oncology bacterial infections; induction chemotherapy; infection-associated mortality; intermediate risk; burkitt's lymphoma; MIDDLE-INCOME COUNTRIES; CHILDHOOD-CANCER; CHILDREN; EXPERIENCE; MANAGEMENT;
D O I
10.7759/cureus.40365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Burkitt's lymphoma (BL) in the pediatric population has significant burden in developing countries. Infection-related complications during the induction chemotherapy phase pose a major challenge and contribute to high mortality rates due to a severely immunocompromised state. However, there is scarce data on the etiologies and optimal management strategies for infection-related mortality in pediatric BL patients, especially in developing countries like Pakistan.Methods This is a cross-sectional study that included a total of 116 pediatric patients with intermediate-risk BL. All patients were treated based on the Children's Cancer and Leukaemia Group (CCLG) 2020 guidelines. Data on patient demographics, presenting symptoms, diagnosis, infectious etiologies, and outcomes were collected. Infection-related complications and mortality were monitored during the induction chemotherapy period. The results of relevant culture reports were tabulated and data were analyzed.Results Among the 116 included patients, 61.1% were males with a mean age of 4.83 & PLUSMN; 2.12 years. Abdominal BL was the most common anatomical location. During the induction period, 66 patients (56.9%) had culture-proven infections, resulting in 33 deaths (28.4%). Fever was the predominant presenting symptom in all patients, followed by vomiting (57.6%), loose stools (42.4%), and cough (18.2%). Neutropenic colitis, sepsis, pneumonia, and meningitis were among the diagnosed infections. Hospital-acquired bacterial infections, including multi-drug resistant gram-negative and gram-positive organisms, were the main cause of mortality, with fungal infections and cytomegalovirus viremia also identified in a few patients. Conclusions This study highlights the urgent need for improved management strategies in pediatric BL patients in Pakistan to reduce infection-related complications and mortality rates, emphasizing the importance of context-specific approaches for infection prevention and management.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group
    Marks, Lianna J.
    Pei, Qinglin
    Bush, Rizvan
    Buxton, Allen
    Appel, Burton
    Kelly, Kara M.
    Schwartz, Cindy L.
    Friedman, Debra L.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (12)
  • [2] Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: A report from the soft tissue sarcoma committee of the children's oncology group
    Spunt, SL
    Smith, LM
    Ruymann, FB
    Qualman, SJ
    Donaldson, SS
    Rodeberg, DA
    Anderson, JR
    Crist, WM
    Link, MP
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6072 - 6079
  • [3] Intestinal Mucor Infection in a Patient with Non-Hodgkin's Lymphoma During Induction Chemotherapy
    Erbay, A.
    Sarialioglu, F.
    Yazici, N.
    Ezer, S.
    Hasbay, B.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S479 - S480
  • [4] Intermediate-Risk Lymphocyte-Predominant Hodgkin Lymphoma: AHOD0031: A Report from the Children's Oncology Group
    Marks, Lianna J.
    Pei, Qinglin
    Buxton, Allen
    Appel, Burton
    Kelly, Kara M.
    Schwartz, Cindy L.
    Friedman, Debra L.
    BLOOD, 2016, 128 (22)
  • [5] IDH Mutated AML Is Associated with Increased Risk of Pulmonary Morbidity and Mortality during Induction Chemotherapy
    Mccall, Wyatt
    Pratz, Keith W.
    Matthews, Andrew H.
    BLOOD, 2024, 144 : 1493 - 1493
  • [6] Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy
    Kurtti, Amanda
    Fritz, Kelly
    Elofson-Disney, Kathryn
    Benefield, Russell
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (06) : 1301 - 1305
  • [7] Outcome of advanced stage (III/IV) intermediate-risk patients with mature B-NHL using rituximab plus FAB group B4 chemotherapy: a Children's Oncology Group report
    Goldman, S.
    Smith, L.
    Anderson, J. R.
    Perkins, S.
    Harrison, L.
    Shiramizu, B.
    Sanger, W.
    Barth, M.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 24 - 24
  • [8] Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia
    J. Y. Zhang
    L. Li
    W. Liu
    Y. Jin
    M. Zhao
    Y. Zhou
    Z. Fan
    Clinical and Translational Oncology, 2021, 23 : 48 - 57
  • [9] Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia
    Zhang, J. Y.
    Li, L.
    Liu, W.
    Jin, Y.
    Zhao, M.
    Zhou, Y.
    Fan, Z.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (01): : 48 - 57
  • [10] Factors Associated with Prolonged Hospital Stay during Induction Chemotherapy for High Risk Pediatric Acute Lymphoblastic Leukemia
    Warrick, Kasper
    Althouse, Sandra K.
    Rahrig, April
    Joy, Rupenthal
    Batra, Sandeep
    BLOOD, 2017, 130